Skip to main content

Catalio Capital Management — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$9.5B
Total invested
$75.8M
Avg. check
23
Industries
Biotechnology 16Health Care 13Medical 10Life Science 9Biopharma 7Pharmaceutical 6+17 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 132
EGenesis
September 2024

EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.

Biopharma · Cambridge$191.0M Series D
Fractyl Health
September 2025

Fractyl Health is a biotechnology company that provides curative therapies for metabolic diseases.

Biotechnology · Lexington$60.0M Post-IPO Equity
Volastra Therapeutics
September 2025

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.

Biotechnology · New York$30.1M Series A
Centenara Labs
September 2023

Centenara Labs is an integrated biotechnology platform company that invests in people and ideas to develop therapies.

Biotechnology · SchlierenDebt Financing
Noetik
September 2024

Noetik is an AI-native biotechnology company that applies machine learning to large-scale human multimodal spatial omics datasets.

Artificial Intelligence (AI) · South San Francisco$1.0M Grant
TapestryHealth
August 2023

TapestryHealth provides telemedicine services including primary care, emergency care, and various health screenings.

Assisted Living · Stratford$25.0M Debt Financing
Leo Cancer Care
July 2026

Leo Cancer Care develops radiation therapy technologies that support cancer treatment in an upright patient position.

Health Care · Harley$65.0M Series D
Ratio Therapeutics
July 2026

Ratio Therapeutics is a clinical-phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.

Biopharma · Boston$70.0M Series C
Claris Biotherapeutics
July 2026

Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.

Biopharma · Jersey City$118.0M Series B
Cambrian Biopharma
July 2026

Cambrian is a distributed development company building therapeutics to lengthen health span.

Biopharma · New York$123.8M Venture - Series Unknown
AdvanCell
July 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.

Biotechnology · Sydney$315.0M Series D
Bayesian Health
July 2021

Bayesian Health is an adaptive AI platform that offers health systems through clinical AI.

Artificial Intelligence (AI) · New York$15.0M Venture - Series Unknown
Septerna
July 2023

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

Biotechnology · San Francisco$150.0M Series B
Anagenex
June 2022

Anagenex is a seed stage biotechnology company building a novel platform for drug discovery focusing on difficult targets.

Biotechnology · Lexington$30.0M Series A
Flourish
June 2026

Flourish Labs combines humans, AI & tech to provide employee coaching and AI-powered peer mental health support.

Artificial Intelligence (AI) · New York$500.0M Series A
Axena Health
June 2024

Axena Health develops commercial-stage medical devices for women's pelvic health.

Health Care · Newton$9.4M Series A
Visby Medical
June 2025

Visby Medical is a diagnostics company that develops polymerase chain reaction diagnostic tests for the detection of infectious diseases.

Health Care · San Jose$55.0M Venture - Series Unknown
Parabilis Medicines
June 2026

Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

Biopharma · Cambridge$75.0M Post-IPO Equity
Thea
May 2026

Thea is an AI-powered skincare and dermatology app that gives personalized skincare advice, product recommendations.

Artificial Intelligence (AI) · New York$4.0M Pre-Seed
Odyssey Therapeutics
May 2026

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

Biotechnology · Boston$25.0M Post-IPO Equity
Cartography Biosciences
May 2026

Cartography is an oncology company that develops cancer immunotherapies that target novel and highly specific tumor antigens.

Biopharma · South San FranciscoVenture - Series Unknown
Cage Pharma
May 2024

Cage Pharma is a pre-clinical biopharmaceutical company that develops new drugs targeting the metabolism of tumors.

Biopharma · Baltimore$137K Venture - Series Unknown
9amHealth
May 2026

9amHealth offers a simplified approach to whole body health, focusing on weight loss, diabetes management, and heart health.

Health Care · Encinitas$26.0M Series B
ArriVent
May 2026

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

Biotechnology · Pennsylvania Furnace$250.0M Post-IPO Equity

Where Catalio Capital Management invests

Biotechnology16
Health Care13
Medical10
Life Science9
Biopharma7
Pharmaceutical6

About Catalio Capital Management's portfolio

How many companies has Catalio Capital Management invested in?

Catalio Capital Management has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Catalio Capital Management invest in?

Catalio Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Biopharma. The firm invests across 23 different industry categories.

What is Catalio Capital Management's largest investment?

Among tracked funding rounds, Flourish received $500.0M in a Series A round. Catalio Capital Management's total known invested capital is $9.5B.

What is the average investment size for Catalio Capital Management?

Catalio Capital Management's average investment size is $75.8M across its portfolio of 132 companies.

What are Catalio Capital Management's most recent investments?

Recent Catalio Capital Management portfolio additions include EGenesis, Fractyl Health, Volastra Therapeutics, Centenara Labs, Noetik. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →